April 28, 1990 |
Amgen, a biotechnology company in Thousand Oaks, lost a round Friday in its complex legal fight with rival Genetics Institute over U.S. marketing rights for a new anti-anemia drug. Genetics Institute, based in Cambridge, Mass., and its partner, Chugai Pharmaceutical Co. of Japan, said a U.S. Appeals Court dismissed Amgen's appeal of an order by the International Trade Commission that would permit Genetics Institute and Chugai to import their version of the drug from Japan to the U.S.
CALIFORNIA | LOCAL
January 25, 1995
A sickle cell anemia self-help organization has appealed for $1,000 to bury a 1-year-old boy who died of the disease. "Whatever it takes to get this baby out of the morgue, that is what we're going to do," said Sister Somayah, an Islamic spiritualist representing Crescent Alliance Self-Help for Sickle Cell. The coroner's office "won't release the body until all arrangements have been made," Somayah said, adding that the organization already has raised $500 for the burial. She said her group hopes a cemetery will volunteer to take the body, even if there is only a $500 down payment.
July 8, 2006 |
An administrative law judge has allowed drug maker Roche Holding Ltd. to continue to import an experimental anemia drug at the center of a patent fight between Roche and Amgen Inc., the companies said Friday. The judge at the U.S. International Trade Commission has determined that Roche can import its experimental drug peg-EPO, also known as Cera, under an exception for clinical trials, the companies said.
November 17, 2006 |
A study linking higher doses of a Johnson & Johnson anemia drug to heart risk prompted a U.S. lawmaker to renew questions about Medicare's policy on Amgen Inc.'s identical medicine. The Medicare plan for the elderly and disabled, including people with failed kidneys, is buying excess doses of the erythropoietin anemia drug, Rep. Bill Thomas (R-Bakersfield), chairman of the House Ways and Means Committee, said in a letter Wednesday.
February 4, 1989 |
Amgen Inc., a Thousand Oaks biotechnology company already embroiled in patent lawsuits over its new anti-anemia drug, has been hit with another suit from its own marketing partner, consumer products giant Johnson & Johnson. Ortho Pharmaceutical, a Johnson & Johnson unit, asked a federal court in Delaware to block Amgen's effort to get federal approval for the drug and to begin marketing it.
August 2, 1994 |
Drug maker Carter-Wallace Inc. told doctors Monday to take their patients off the epilepsy drug Felbatol after two people who took it died from a serious form of anemia, a development that led to the company's stock losing a third of its value. The Food and Drug Administration and the company said 10 patients contracted a rare and frequently fatal affliction called aplastic anemia, in which the bone marrow stops making blood cells.
April 8, 1998 |
The National Academy of Sciences recommended for the first time Tuesday that large segments of the population take vitamins. All women of childbearing age should take a daily folic acid supplement to cut the risk of serious birth defects, and all older adults should take daily vitamin B12 supplements to guard against anemia, the academy recommended.
April 21, 2000 |
A widely used new blood thinner that is routinely given to heart patients after angioplasty appears in rare cases to trigger a deadly blood disease. The drug, called clopidogrel (trade named Plavix) prevents blood clots and has been taken by more than 3 million people worldwide since its introduction two years ago. For the first time, doctors have linked the medicine to thrombotic thrombocytopenic purpura, or TTP, a dangerous form of anemia.
CALIFORNIA | LOCAL
July 12, 1994 |
For thousands of people across the country with leukemia and other blood diseases, the chance of finding a life-saving bone marrow donor can be as little as one in 100. But for 17-year-old Lisa Mederos, the odds are closer to one in a million. It's not Mederos' illness--a potentially fatal type of anemia--that makes her chances so slim. It's her ethnicity.
June 25, 1998 |
Shares of Amgen Inc., the world's largest biotechnology company, rose 6.5% as the government confirmed that Medicare will pay for the company's anemia treatment Epogen even if the drug boosts red blood cells over an earlier limit. Amgen's stock rose $4.06 to close at $66.75 in Nasdaq trading. The shares earlier hit a 52-week high of $67.25. Thousand Oaks-based Amgen could sell more Epogen because the federal government changed a 1997 rule on Medicare reimbursement for the drug.